KMT2A and acute myeloid leukemia: For example, the KOMET-007 trial, which includes multiple arms, explored the addition of ziftomenib to the standard 7+3 induction regimen (cytarabine and daunorubicin) for newly diagnosed (ND) AML with NPM1 mutations or KMT2A rearrangements.